Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-α therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and mortality. However, there is a low reported incidence of conversion to positive TBC status among patients with psoriasis treated with second-generation biologic therapies, particularly anti-interleukin (IL)-17 therapies such as secukinumab.
Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection / Megna, M., Patruno, C., Rita Bongiorno, M., Gambardella, A., Guarneri, C., Foti, C., Lembo, S., Loconsole, F., Fabbrocini, G.. - In: JOURNAL OF DERMATOLOGICAL TREATMENT. - ISSN 1471-1753. - (2022), pp. 1-5. [10.1080/09546634.2022.2062280]
Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection
Matteo Megna
;Cataldo Patruno;Alessio Gambardella;Serena Lembo;Gabriella Fabbrocini
2022
Abstract
Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-α therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and mortality. However, there is a low reported incidence of conversion to positive TBC status among patients with psoriasis treated with second-generation biologic therapies, particularly anti-interleukin (IL)-17 therapies such as secukinumab.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
